These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11328624)

  • 21. Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma.
    Raphael BA; Morrissey KA; Kim EJ; Vittorio CC; Rook AH
    J Am Acad Dermatol; 2011 Jul; 65(1):212-4. PubMed ID: 21679821
    [No Abstract]   [Full Text] [Related]  

  • 22. Topical treatment of early cutaneous T-cell lymphoma.
    Ramsay DL; Meller JA; Zackheim HS
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous T cell lymphoma: update of treatment.
    Zackheim HS
    Dermatology; 1999; 199(2):102-5. PubMed ID: 10559573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
    Dummer R; Foss F; Dreno B; Bagot M
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
    Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic alternatives in cutaneous T-cell lymphoma.
    Holloway KB; Flowers FP; Ramos-Caro FA
    J Am Acad Dermatol; 1992 Sep; 27(3):367-78. PubMed ID: 1383293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches.
    Querfeld C; Rosen ST; Kuzel TM; Guitart J
    Semin Cutan Med Surg; 2003 Sep; 22(3):150-61. PubMed ID: 14649582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
    J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of cutaneous T-cell lymphoma: an update.
    Young JW
    J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
    Musolino A; Panebianco M; Zendri E; Santini M; Di Nuzzo S; Ardizzoni A
    Br J Haematol; 2009 Apr; 145(1):84-6. PubMed ID: 19208096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.
    Sepmeyer JA; Greer JP; Koyama T; Zic JA
    J Am Acad Dermatol; 2007 Apr; 56(4):584-7. PubMed ID: 17184879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
    Ruiz-de-Casas A; Carrizosa-Esquivel A; Herrera-Saval A; Rios-Martín JJ; Camacho F
    Br J Dermatol; 2006 Feb; 154(2):372-4. PubMed ID: 16433814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
    Huen AO; Kim EJ
    Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of cutaneous T-cell lymphoma with retinoids.
    Zhang C; Duvic M
    Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK; Lebwohl M
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
    Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination treatment in CTCL: the current role of bexarotene.
    Delfino C; Grandi V; Pileri A; Rupoli S; Quaglino P; Alterini R; Goteri G; Canafoglia L; Pimpinelli N
    G Ital Dermatol Venereol; 2012 Dec; 147(6):573-80. PubMed ID: 23149703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bexarotene and systemic disease progression in CTCL?
    Dummer R; Hauschild A; Skalsky J; Burg G; Weichenthal M
    J Am Acad Dermatol; 2006 Aug; 55(2):365-6; author reply 366. PubMed ID: 16844539
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.